This HTML5 document contains 229 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n6http://dx.doi.org/10.3324/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34255145
rdf:type
wikibase:Item
schema:description
2010年论文 teaduslik artikkel 2010 nî lūn-bûn научна статия ২০১০-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ vitenskapelig artikkel مقالة علمية 2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած article scientific 2010年论文 bài báo khoa học wetenschappelijk artikel artikull shkencor სამეცნიერო სტატია artículo científico publicado en 2010 2010年論文 article científic articolo scientifico vitskapeleg artikkel 2010年论文 artigo científico artigo científico (publicado na 2010) επιστημονικό άρθρο 2010 թվականի հուլիսին հրատարակված գիտական հոդված 2010年論文 tieteellinen artikkeli научни чланак 2010년 논문 مقالهٔ علمی 2010年の論文 научная статья 2010年論文 mokslinis straipsnis article scientifique (publié 2010) vědecký článek artikulong pang-agham scientific article artículu científicu espublizáu en 2010 บทความทางวิทยาศาสตร์ 2010年論文 научни чланак vetenskaplig artikel bilimsel makale 2010年论文 سائنسی مضمون tudományos cikk wissenschaftlicher Artikel мақолаи илмӣ artigo científico (publicado na 2010) наукова стаття, опублікована в липні 2010 מאמר מדעי naučni članak 2010年論文 artykuł naukowy vedecký článok videnskabelig artikel (udgivet 2010) 2010年论文 scienca artikolo мақолаи илмӣ articol științific 2010年论文
p:P577
wds:Q34255145-1FC57E1F-493B-4A5E-BCAC-098133489715
wdt:P577
2010-07-27T00:00:00Z
p:P2860
wds:Q34255145-80872184-9352-404E-B25D-409E5E0E4330 wds:Q34255145-843B978D-71CF-4A6B-B2D6-FAA1DDFE6A1B wds:Q34255145-8654B497-80D1-41DB-8F7D-EFC6F662FD0E wds:Q34255145-7290E5AE-A99E-4EAD-8C6A-2DEF12DE6E82 wds:Q34255145-74AAECDC-6113-4094-ABF2-D77A6B72F82B wds:Q34255145-766A9E13-8C20-4015-902B-9C1D6BAAE9F9 wds:Q34255145-5C0120DE-EC80-4BB5-B37F-DE286926E7CF wds:Q34255145-6398EA58-16E0-43B1-9FBF-F86133341B94 wds:Q34255145-6FE20DE8-C675-4441-97AF-A20914ECE08C wds:Q34255145-52B780C4-17AB-4497-AF4D-9EDE28854D44 wds:Q34255145-5366282A-6A83-4253-9BB2-C3AD820B8C17 wds:Q34255145-567731F8-F252-48D1-AB31-6A097F2CCFE8 wds:Q34255145-5996C346-AECE-4EDD-A99E-1C0C47D91E23 wds:Q34255145-A10EDAE2-CBB3-4378-AAF1-257E43D32D22 wds:Q34255145-A1B8DF1F-03FF-42AB-9FC6-AFDB351AFF5F wds:Q34255145-A88264B2-3E96-4F27-AA46-77CAD1F42829 wds:Q34255145-9637070D-592E-4B8A-9EC5-BEC9436F3EBF wds:Q34255145-95C0A94D-EB97-4F5A-AFE7-7B4D9BD200D7 wds:Q34255145-8F0B9AAF-EE56-4105-9DC1-E33B93649023 wds:Q34255145-90A40B91-B556-42EC-BCDD-DE97E9C43FBE wds:Q34255145-1400A88E-0068-438A-A099-E58F14F60323 wds:Q34255145-191A3306-AAC2-4298-9F68-10070C23492D wds:Q34255145-1A0D72F5-224E-47AB-8EB4-3D865FB1B427 wds:Q34255145-4A25A7D2-D2DE-4E0D-A451-029CD0B10478 wds:Q34255145-4A513C56-559F-43D7-8A16-B44A213A7281 wds:Q34255145-4D6187BD-9B92-44E0-AB43-2F0E1951FAD3 wds:Q34255145-52A5517D-2D5D-4856-B2F8-E42E1D84969B wds:Q34255145-3D544B4C-A0E8-4592-BCFF-83F2B50A8CEE wds:Q34255145-4124C136-0F1B-45DE-B4B5-883CB9978CFD wds:Q34255145-2CEA02F3-B6D9-4A9A-96B8-C0F0DD1E13E5 wds:Q34255145-1F37CB9D-6929-4D62-B24D-FA8F2B7AD97D wds:Q34255145-2291A0CD-B547-4F63-8C70-B70EFFB195A7 wds:Q34255145-DF1DFD33-4C45-4080-8E70-BE7DE013A7D1 wds:Q34255145-E91AC058-2D87-45FC-A615-B3F8312B31E7 wds:Q34255145-E999D593-FF05-472D-A707-30511FA29F7C wds:Q34255145-CD4A458B-90E0-4936-BB58-F460EADDD3A4 wds:Q34255145-DC8573A5-B8A0-453C-845F-189C8B0FB865 wds:Q34255145-B7999A1A-5611-49B1-AFA1-021EF907C0A6 wds:Q34255145-BC11B29D-75DA-41A1-BA24-CE043636AA7C wds:Q34255145-AA13BA52-817E-4914-9B02-E659695B4821 wds:Q34255145-AC3DA79E-1BB5-42F9-BBE2-DA702CF92801 wds:Q34255145-B0DA31FD-6421-4403-AA87-B326581D2E5E wds:Q34255145-FD265279-B5AC-4B3B-A786-A6AFBB8B9582 wds:Q34255145-EA96CDF8-A85F-4831-A1DA-58E96CCBD4FC wds:Q34255145-F5D72E2C-A2F4-46A0-8C8D-7C8A942C011A
wdt:P2860
wd:Q28377983 wd:Q53825920 wd:Q71059756 wd:Q24655964 wd:Q70861940 wd:Q69052018 wd:Q39688572 wd:Q70215525 wd:Q61868384 wd:Q83013957 wd:Q54230497 wd:Q54227492 wd:Q43405306 wd:Q72233372 wd:Q73883334 wd:Q68087499 wd:Q73644952 wd:Q60203798 wd:Q34195428 wd:Q68180035 wd:Q36478461 wd:Q40721259 wd:Q46253134 wd:Q36969778 wd:Q43250016 wd:Q46445579 wd:Q40153014 wd:Q34408882 wd:Q48568887 wd:Q34668052 wd:Q37324251 wd:Q83180900 wd:Q46131298 wd:Q54523910 wd:Q44817133 wd:Q72562480 wd:Q37239527 wd:Q81606574 wd:Q40625085 wd:Q82192536 wd:Q37143728 wd:Q71123629 wd:Q37126959 wd:Q33340726 wd:Q47841773
p:P2093
wds:Q34255145-46FEA174-FE12-488D-9F8D-4C47BE743AFC wds:Q34255145-3DC3126B-1D34-4450-92AE-64BD1075D734 wds:Q34255145-3C2AF54E-6B9B-4D1D-9096-3EEE22947BF3 wds:Q34255145-06FE95E1-48E8-4DB2-8254-1175552AAB63 wds:Q34255145-038AA0C3-F9AA-4DF0-8AE8-DC98A5913761 wds:Q34255145-0B2A96B9-D81B-4092-BB7F-AE489880D0A6 wds:Q34255145-9EEF31BF-BB99-4B25-91B5-69B7EF50A083 wds:Q34255145-9C38F705-F6BC-43DB-8193-DAA67B5EAB97 wds:Q34255145-9FB61C1A-763A-4541-8897-E53900EE08E1 wds:Q34255145-90A50087-EB41-485C-A4FB-738D8789D302 wds:Q34255145-89A7BAF8-E6CE-405A-8A93-729AC910D4E6 wds:Q34255145-91ED0671-FFA1-4DCE-9A11-007AE9DB1AC7 wds:Q34255145-7FFCB033-6BF2-497B-B2DE-B959EF1C20CC wds:Q34255145-EB5A0A77-3368-4385-9CBF-A6EA4F01A76B wds:Q34255145-EA2E9B98-6E90-41BE-943A-B039704DDE46 wds:Q34255145-AA5D113A-68C2-4EAF-B6BB-9D64A6BC482F wds:Q34255145-B9BEF818-A49A-4716-9B07-9CE05CC8E310 wds:Q34255145-B91A10B4-58B7-42C2-857C-4C74E942B9BE
wdt:P2093
Lourdes Escoda Grupo Español de MM and Programa para el Estudio de la Terapéutica en Hemopatía Maligna Cooperative Study Groups Dolores Carrera Jesús F San Miguel Maria Victoria Mateos Miguel T Hernández-García Juan José Lahuerta Anna Sureda Concepción Rivas-González Joan Besalduch Javier de la Rubia Adrían Alegre Carlos Grande Javier García-Frade Joan Bladé Felipe de Arriba Joaquín Díaz-Mediavilla José García-Laraña
rdfs:label
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
skos:prefLabel
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
schema:name
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study.
p:P50
wds:Q34255145-93C9C3D0-93FD-4AA0-AC46-41FEEA37F277 wds:Q34255145-3063DAD9-2727-4597-80C5-4706DE813E6F wds:Q34255145-0074FAF9-5987-4555-95A2-F55E5AF4AC1A
wdt:P50
wd:Q47344831 wd:Q63688958 wd:Q87885216
p:P1476
wds:Q34255145-D8C801A8-E946-467B-AB6C-D4C52DEAD14A
wdt:P1476
Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
p:P304
wds:Q34255145-047EA9E8-DE74-41D5-8D2B-B3F86091E04D
wdt:P304
1913-1920
p:P31
wds:Q34255145-714C30FF-E3FE-4E52-B891-14713A959C25
wdt:P31
wd:Q13442814
p:P921
wds:Q34255145-2B6D20E5-904F-4081-A5DA-E8439C44A576
wdt:P921
wd:Q467635
p:P698
wds:Q34255145-02EB8F4B-279F-40F5-9793-E6638C8747DB
wdtn:P698
n12:20663944
wdt:P698
20663944
p:P1433
wds:Q34255145-937742F9-7353-4A89-A48E-7478CAD7A664
wdt:P1433
wd:Q5638209
p:P433
wds:Q34255145-1B96F6E5-BEFD-4781-A9E3-28F915AD4B62
p:P478
wds:Q34255145-5BE70A09-2CF5-42CE-9AF3-2761A4FBEC6C
wdt:P433
11
wdt:P478
95
p:P356
wds:Q34255145-9DB80823-58B2-4EC4-B1AA-29EE204B8E81
wdtn:P356
n6:HAEMATOL.2010.028027
wdt:P356
10.3324/HAEMATOL.2010.028027
p:P5875
wds:Q34255145-F606A61A-5307-48DC-B155-70FD4A56702D
wdt:P5875
45388900
p:P932
wds:Q34255145-D61A6A37-1168-44A9-B437-90F4018E3DAA
wdt:P932
2966914